Blood glucose control sits at the centre of diabetes care, and it is often assumed that tightening it will speed a foot ulcer toward closure. The published evidence is more nuanced. Glycemic control matters a great deal for whether an ulcer develops at all and whether a limb is ultimately lost, but the evidence that lowering HbA1c accelerates healing of an ulcer that already exists is surprisingly thin.
Hyperglycemia and the Risk of Ulceration
Chronic hyperglycemia drives the two pathologies that make a diabetic foot vulnerable: distal symmetric polyneuropathy and peripheral arterial disease. A 2023 meta-analysis by Tang and colleagues in Vascular, pooling 26 studies, found elevated glycated hemoglobin to be a significant risk factor for developing a foot ulcer (mean difference 1.24, 95% CI 0.94–1.54). The same analysis quantified the comorbidities that travel with poor metabolic control: coexisting neuropathy carried an odds ratio of 4.80 for ulceration, retinopathy 3.37, and nephropathy 3.15.
These findings are consistent with risk-prediction work. Chen and colleagues, writing in Diabetes Research and Clinical Practice in 2021, developed and externally validated a scoring model for incident foot ulceration in type 2 diabetes. HbA1c was retained as one of nine weighted predictors alongside neuropathy, retinopathy, nephropathy, intermittent claudication, smoking, and — as a protective factor — regular foot care.
Does Tighter Control Heal an Existing Ulcer?
Here the evidence base is strikingly empty. A Cochrane systematic review by Fernando and colleagues, published in 2016, set out to compare intensive versus conventional glycemic control for treating active diabetic foot ulcers. Despite an exhaustive search of trial registries and databases, the authors identified only a single eligible randomised controlled trial, and it reported no results. Their conclusion was explicit: it is not possible to say whether intensive glycemic control helps or harms the healing of an established foot ulcer.
Observational data partly fill the gap. A 2020 systematic review and meta-analysis by Lane and colleagues in the Journal of Diabetes and Its Complications, covering 47 studies and more than 12,600 ulcers, found no association between HbA1c category and wound healing. A prospective cohort of 99 patients reported by Vella, Gatt, and Formosa in the Journal of the American Podiatric Medical Association reached a similar conclusion: baseline HbA1c did not predict whether an ulcer resolved or ended in amputation. It did, however, correlate significantly with time to healing among the 77 ulcers that closed, suggesting hyperglycemia may slow the trajectory even where it does not determine the endpoint.
Where Glycemic Control Clearly Matters: Limb Loss
The same Lane meta-analysis that found no healing signal found a strong and consistent one for amputation. Pooled across cohort studies, an HbA1c of 8% or greater was associated with an odds ratio of 4.80 (95% CI 2.83–8.13) for lower extremity amputation compared with values below 8%. Fasting glucose of 126 mg/dL or higher carried a pooled odds ratio of 1.46. The authors flagged residual confounding, since many contributing studies did not adjust for vascular status or renal function, but the association was durable across subgroups.
Glycemic control also appears to influence the durability of revascularisation. Meloni and colleagues followed 304 patients with ischemic diabetic foot ulcers treated by angioplasty and reported in Advances in Wound Care that 24.3% required a repeat procedure within a mean of 3.5 months. Glycated hemoglobin and dialysis dependence were the two independent predictors of recurrent critical limb ischemia, and those patients fared markedly worse: 24.3% major amputation versus 4.3%, and 33.3% mortality versus 7.9%.
Beyond HbA1c: Glycemic Variability and Time in Range
HbA1c averages roughly three months of glycemia and conceals swings. Li and colleagues examined time in range in BMC Surgery in 2022, using propensity-score matching in patients undergoing toe or partial foot amputation. Those with time in range below 70% during hospitalisation had higher rates of re-amputation and postoperative infection, and this remained an independent risk factor for re-amputation on multivariate analysis. Notably, the association held even in the subgroup with HbA1c below 7.5% — implying that a reassuring HbA1c can mask perioperative glycemic instability that carries real surgical consequence.
A Caution Against Reflexive Intensification
Lower is not automatically better in every patient. Aragón-Sánchez and colleagues analysed 245 patients with moderate to severe diabetic foot infections and reported in Advances in Wound Care that HbA1c below 7% was a risk factor for mid-term mortality (HR 4.9, 95% CI 1.8–13.2), alongside osteomyelitis and reduced eGFR. The likeliest explanation is confounding by frailty and comorbidity rather than harm from good control itself: patients who are cachectic, renally impaired, or malnourished often run low HbA1c values. An HbA1c figure must be interpreted against the whole patient, not treated as an isolated target.
Clinical Summary
Three conclusions follow from this literature. Hyperglycemia is a well-established risk factor for developing a diabetic foot ulcer, acting largely through neuropathy and vascular disease. There is no randomised evidence that intensifying glycemic control speeds the healing of an ulcer already present, and observational data show no clear healing signal, although poorer control may lengthen time to closure. And the association between elevated HbA1c and lower extremity amputation is strong and reproducible, as is the association between glycemic instability and re-amputation. Glycemic management therefore belongs in diabetic foot care as a prevention and limb-preservation strategy, deployed alongside offloading, infection control, and revascularisation rather than as a substitute for them, and individualised to the patient’s age, renal function, and overall health status.
References
Sources were identified through PubMed.
- Tang WH, Zhao YN, Cheng ZX, et al. Risk factors for diabetic foot ulcers: A systematic review and meta-analysis. Vascular. 2023;32(3):661–669. doi:10.1177/17085381231154805
- Chen D, Wang M, Shang X, et al. Development and validation of an incidence risk prediction model for early foot ulcer in diabetes based on a high evidence systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2021;180:109040. doi:10.1016/j.diabres.2021.109040
- Fernando ME, Seneviratne RM, Tan YM, et al. Intensive versus conventional glycaemic control for treating diabetic foot ulcers. Cochrane Database of Systematic Reviews. 2016;(1):CD010764. doi:10.1002/14651858.CD010764.pub2
- Lane KL, Abusamaan MS, Voss BF, et al. Glycemic control and diabetic foot ulcer outcomes: A systematic review and meta-analysis of observational studies. Journal of Diabetes and Its Complications. 2020;34(10):107638. doi:10.1016/j.jdiacomp.2020.107638
- Vella L, Gatt A, Formosa C. Does baseline hemoglobin A1c level predict diabetic foot ulcer outcome or wound healing time? Journal of the American Podiatric Medical Association. 2017;107(4):272–279. doi:10.7547/15-176
- Meloni M, Izzo V, Giurato L, et al. Recurrence of critical limb ischemia after endovascular intervention in patients with diabetic foot ulcers. Advances in Wound Care. 2018;7(6):171–176. doi:10.1089/wound.2017.0778
- Li S, Huang ZX, Lou DH, Jiang YY, Zhao S. Impact of time in range during hospitalization on clinical outcomes in diabetic patients with toe amputation: a propensity score matching analysis. BMC Surgery. 2022;22(1):314. doi:10.1186/s12893-022-01762-1
- Aragón-Sánchez J, Víquez-Molina G, López-Valverde ME, Rojas-Bonilla JM, Murillo-Vargas C. Does metabolic control have any influence on the clinical presentation and short-term outcomes of diabetic foot infections? Advances in Wound Care. 2021;12(3):135–144. doi:10.1089/wound.2021.0072
Comments
